

ANNUAL REPORT AND ACCOUNTS

2024-2025



**THE
BRAIN
TUMOUR
CHARITY**



CONTENTS

Chair's report	4
CEO's report	5
Strategic report	6-33
Thanks	34-35
Trustees and governance	36-39
Independent auditor's report	40-43
Statement of financial activities	44
Balance sheet	45
Consolidated Statement of cash flows	46
Notes to the accounts	47-61

OUR VISION, GOALS AND VALUES

OUR VISION

Our vision is for everybody diagnosed with a brain tumour to live longer, better lives.

OUR GOALS

We'll achieve our vision by:

TRANSFORMING THE RESEARCH LANDSCAPE

We're committed to funding the world-class research that moves us further, faster towards cures for all brain tumours. However, we also need to invest in transforming the research landscape so that breakthroughs in the lab become new treatments that are available to the community.

RAISING VOICES TO CAMPAIGN FOR CHANGE

We're more powerful when we join forces to call for change. That's why we're dedicated to bringing together people who share our goals and helping them become voices for change - whether that's persuading policymakers to go further, faster in defeating brain tumours or raising vital funds to power our work.

IMPROVING QUALITY OF LIFE AND PROVIDING SUPPORT AND BEST CARE FOR EVERYONE

We're committed to making sure that everybody in the brain tumour community - no matter who they are or where they're being treated - has access to the care and support they need.

OUR VALUES

Our values underpin everything we do. They define what we believe and guide our actions every day.

The way we work is always:

COMMUNITY FIRST

We put the community's needs first, ensuring our work is informed by those with lived experience and that they are the driving force behind our decisions. We include everyone, amplifying their voices and uniting in our shared purpose to create change

COLLABORATIVE

We know that we're stronger together, so we choose to lean on each other, share openly and utilise expertise and knowledge wherever it exists. We seek out and support diverse perspectives, operate without ego and are part of a connected eco-system that everyone can join.

BOLD

We're unapologetically ambitious and true to ourselves. We'll be confident and relentless in challenging the status quo, even when that means making difficult decisions. We're determined, focused and unstoppable.

INNOVATIVE

We're creative and adopt a growth mindset, always using our experience and imaginations to find smarter and more effective ways to propel progress. We're not afraid to think differently, find new ways to solve problems and be agile in 'testing and learning', so we can move at pace in pursuit of our vision.



CHAIR'S REPORT

If you were to ask me for a single word that described 2024/25 for The Brain Tumour Charity, it would have to be “transformative”.

Across the entire organisation, teams have been undergoing programmes of work that have laid the foundations for us to deliver on our ambitious strategy that runs until 2030.

Underpinning all of this is the work of our fundraising team. Not only has it been a record-breaking year for fundraising – achieving an incredible income of £15.3m – but we’ve also developed a new dedicated fundraising strategy. This piece of work will prove to be vital in helping us grow our income to match our ambitious goals and empower us to move further, faster for people affected by brain tumours.

Of course, I can’t talk about fundraising without mentioning the monumental impact of our partnership with Wickes. Our two-year partnership is now over, but the team at Wickes will forever be part of the DNA of The Charity. Not only have they raised a transformative amount of money – more than £2m over the two years – but they’ve also raised our profile significantly by showcasing our work at more than 230 stores across the UK. A special thank you to them.

As I reflect on my seven years as a Trustee and Chair of The Brain Tumour Charity, I gain a greater perspective and appreciation about the challenges we’ve faced. In overcoming these challenges, we’ve become a stronger, more resilient organisation and this has enabled us to greatly increase our impact without losing our ethos of being led by the brain tumour community.

This is in no small part thanks to the efforts of Neil Dickson, who retired from the Board and as Vice Chair, in September 2024 but continues to support The Charity, along with his wife Angela, as Emeritus Founder Trustees. After the loss of their dear daughter Samantha to a brain tumour, Neil and Angela founded the Samantha Dickson Brain Tumour Trust which would go on to become The Brain Tumour Charity as we know it today – the largest dedicated funder of research into brain tumours globally which continues to go from strength to strength. Thank you so much, Neil and Angela, for what you started.

I’d also like to thank our other retiring Trustees – Sean Hird, Justine McIlroy, Dr Alan Palmer and Beth Worrall – for their incredible support and contribution in taking The Charity forward. And indeed, our serving Trustees who give their time, experience and skills so generously.

And thank you to everybody else who’s stood alongside us. Whether you’re a fundraiser, a donor, a volunteer, campaigner or a member of our team, the achievements that we share in this Annual Report are only possible thanks to your hard work and determination.

Jack Morris CBE
Chair of Trustees



CEO'S REPORT

Achieving meaningful, transformational impact takes more than ambition and moving at pace towards our goals. To make the biggest difference for people affected by brain tumours, we need to actively listen to them and consciously place their lived experience at the heart of everything we do.

I believe this year's Annual Report highlights our ongoing commitment to doing this and showcases the deep connection we share with the brain tumour community.

Nowhere is this more clearly reflected than in our decision to launch two new, innovative grant rounds, which were shaped by the community, who shared their most urgent unmet needs with us.

Our Quality-of-Life Award was introduced in response to a clear need for an evidence-based approach to improving the lives of people diagnosed with a brain tumour. To make sure we funded projects with the greatest potential for achieving meaningful change, we brought together three vitally important groups of people – researchers, healthcare professionals and people personally affected by the disease – to develop these promising ideas into impactful programmes of work (see page 9).

The community was even clearer about the need for new treatments to be developed and become available faster. That's why we also launched our Translational Award that aims to speed up the pace by which important scientific findings in the laboratory are developed into new treatments for patients. I'm confident this new funding will be a catalyst to change for those who have waited far too long for new treatments to emerge (see page 7).

Deciding to fund new programmes of work inevitably means we sometimes have to choose to bring existing projects to an end. After careful evaluation, we decommissioned our BRIAN app in August 2024, so we could invest in the projects we believe will have the greatest

impact on our ability to achieve our mission.

It's this type of difficult decision-making that enabled us to spend £6.2m on innovative research grants during 2024/25. That means, since the launch of our new strategy just two years ago, we've funded more than £11m on world class research into brain tumours and are on course to achieve our goal of awarding more than £50m to researchers by 2030.

But we aren't just looking to the future. We're also helping more people right now through our Support and Information services. This year saw a 6% growth in the number of people we supported with our free counselling service growing by 74%.

This year, we've also been busy working to make sure the unmet needs of the brain tumour community are addressed by the new government. We were proud to support Dr Scott Arthur MP in drafting the Rare Cancers Bill and working collaboratively with charity colleagues to mobilise our communities to achieve the required parliamentary support for its successful passage through early readings.

Perhaps the most significant news from the year was the landmark approval of the combination of dabrafenib and trametinib for treating children diagnosed with BRAF-mutated gliomas. This marks the first positive change in brain tumour treatment in a generation and I'm proud of the role we played – both in our campaigning work today and the research we funded in the past (see page 7).

But none of this would be possible without your support. Only with your help are we able to blend science and compassion year after year, and for that I can only offer my deepest thanks.



Dr Michele Afif
CEO



STRATEGIC REPORT

TRANSFORMING THE RESEARCH LANDSCAPE

We believe that funding the best research globally will propel the most powerful change for everyone diagnosed with a brain tumour – now and in the future.

But we don't just need to fund research projects. We must transform the research landscape to build research capacity, deliver clinical trials and drive translational research to make sure that the discoveries made in labs are turned into real-world benefits for people affected by brain tumours.



DESIGN, DELIVER AND SUPPORT INNOVATION AND IMPACTFUL RESEARCH AWARDS AND GRANTS

By 2030, we aim to invest at least £50m in the best and most pioneering research. We're committed to funding all types of research, from creating new knowledge and speeding up diagnosis to accelerating new treatments through translational research.

Goals for 2024/25

Deliver our first-ever Translational Award grant round and award four Translational grants.

Deliver one Quest for Cures grant round and award two Quest for Cures grants.

Deliver two Expanding Theories grant rounds and award four Expanding Theories grants.

Deliver one Future Leaders Post-Doctoral grant round and award six Future Leaders Post-Doctoral grants.

Provide funding for an early detection symposium.

Outcomes

Delivered our first-ever Translational Award grant round and awarded two Translational grants with one additional grant subject to final agreement.

Delivered one Quest for Cures grant round and awarded two Quest for Cures grants.

Delivered two Expanding Theories grant rounds and awarded four Expanding Theories grants.

Delivered one Future Leaders Post-Doctoral grant round and awarded five Future Leaders Post-Doctoral grants.

Awarded a grant to support an early detection symposium in Manchester.

We also: Co-funded two new grants with Worldwide Cancer Research.

HIGHLIGHTS OF 2024/25

Funding new and pioneering research projects

2024/25 was a landmark year for The Charity as we funded £6.2m of research grants. As well as funding new Future Leaders, Expanding Theories and Quest for Cures grants, we also designed and delivered some pioneering new awards.

For the first-time ever, we opened and awarded our new Translational Award that's specifically designed to move breakthroughs out of labs and make them available to the community. Unfortunately, the nature of these projects means we haven't been able to share information about them at the time of writing, but we're extremely excited about their potential impact.

Towards the end of the year, we were delighted to announce our latest funding collaboration with Worldwide Cancer Research. We'll be co-funding two new projects that are aimed at developing our understanding of Diffuse Midline Glioma – one of the deadliest forms of childhood brain tumour.

A treatment nearly 20 years in the making!

In May 2024, NICE published their final guidance for use of dabrafenib and trametinib for treatment of high and low grade gliomas in children – meaning the treatment would be available through the NHS in England. This was later followed by approval in Northern Ireland, Scotland and Wales.

This approval marked the first new treatment for children with brain tumours in decades to be approved for use in the NHS. Some of the underlying research behind the clinical trials that led to the approval was first discovered thanks to Professor David Jones' research that we funded nearly 20 years ago.

We also played a vital role in the approval process by providing evidence during the NICE appraisal and making sure the voice of the community was represented. Our Trustee Suki Sandhu also attended the appraisal and shared how her family was affected when her son, Raj, was diagnosed with a high grade glioma.

Our research reveals potential new drug to target rare childhood brain tumour

Professor Chris Jones and his team had research published in the Cancer Cell journal that revealed a potential new drug to target Diffuse Hemispheric Glioma (DHG) – a rare and deadly form of brain tumour.

As part of one of our Quest for Cures grants, the team aimed to uncover clues about how DHG cells behave and found a key weakness in the cells that could be targeted by ribociclib.

Ribociclib is a drug already used to treat certain types of breast cancer and after pre-clinical testing, the research moved to trialling ribociclib in a child diagnosed with a DHG after other treatments had failed.

These are very early results as the drug has only been tested in one child for this purpose. However, the results were remarkable.

Treatment with ribociclib resulted in stable disease for a further 17 months after first- and second-line treatment had failed. The child's tumour has since grown back and they are receiving further treatment, more than four years since their diagnosis.

DHGs typically have a prognosis of 18-22 months and the tumour typically starts growing back 3.5 months after treatment – so, no recurrence for 17 months following ribociclib treatment is extremely promising.

To determine how effective ribociclib truly is, it needs to be tested as part of a clinical trial. However, these results are a great starting point to build a clinical trial upon.

New insights may improve treatment for meningiomas

Research funded by The Charity and published in Nature Medicine last year suggests that we may be able to use molecular testing to predict how somebody diagnosed with a meningioma will respond to certain treatments.

Dr Gelareh Zadeh and her team in Toronto built upon their own prior research that found four distinct molecular sub-types of meningioma. This new research advances the knowledge further by accurately predicting how a tumour may respond to treatment, which could help tailor surgical and radiotherapy approaches.

This is a hugely promising discovery as meningiomas are the most common type of adult brain tumour, but they're currently very difficult to predict.

One of our Junior Fellow's research is featured in Cancer Cell

Dr Spencer Watson – one of our Junior Fellows – had his research published in Cancer Cell in 2024/25. His research focuses on understanding why glioblastomas grow back and he'd previously discovered tumours often regrow next to scarred regions in the brain inadvertently caused by treatment.

His newest research used cutting-edge technology his team had previously developed to understand the environment around the tumour in unprecedented detail. This helped them to see exactly how the scars form and how they protect the tumour cells from the immune system.

With this knowledge, the team were able to combine immunotherapy drugs with drugs that prevent scarring. This significantly reduced scar formation in preclinical models, not only decreasing tumour recurrence, but also improving overall survival.



DESIGN AND DELIVER QUALITY-OF-LIFE AWARD

Through our Quality-of-Life Award, we're determined to invest in research that helps us build an evidence-based understanding of how we can improve quality of life for the brain tumour community. Then we can work towards making sure it's embedded into standard practice.

Goals for 2024/25

Design and deliver our first-ever Quality-of-Life Award and award up to £400,000 in Quality-of-Life grants.



Outcomes

Designed and delivered our first-ever Quality-of-Life Award and awarded four Quality-of-Life grants totalling £380,000.

We also: Held our first Quality-of-Life sandpit event on 11 and 12 November 2024.

HIGHLIGHTS OF 2024/25

Bringing together experts to collaborate for a cure

In November 2024, we held our first-ever Quality-of-Life sandpit event. The aim was to bring together a wide variety of experts working in care and research – including researchers, doctors, nurses, psychologists and physiotherapists – to discuss the challenges they face when it comes to improving quality of life for children and young people following treatment for a brain tumour.

These discussions were supported by some of our incredible community members who helped to make sure the lived experiences of people affected by a brain tumour were central and highlight how the disease can impact quality of life.

This is collaboration at its best. Harnessing the connections between different people from across disciplines and experiences to achieve a shared goal.

During the sandpit, project groups were established to develop potential research ideas and brought together different areas of expertise to address some of the challenges that had been identified.

The project groups then met online to develop their ideas further, as well as get feedback on their potential projects from the wider group and expert mentors – helping them create stronger applications for our Quality of Life grant round.

Announcing our new Quality of Life grants

In March 2025, we announced which projects developed during our sandpit event we'd be funding.

In total we awarded

£380,000

across four projects designed to improve quality of life for children and young people living with the effects of a brain tumour.

The four pioneering projects each have a very different focus:

- developing a national approach to making sure children are well supported as they return to education after being diagnosed with a brain tumour
- helping families better understand and manage their child's fatigue
- creating a roadmap for better, evidence-based support for children living with a brain tumour
- understanding how genetics might affect the long-term impact of a brain tumour diagnosis.

ENGAGE THE RESEARCH COMMUNITY

Although we're an organisation that's always punched above its weight, we need to increase the size of our reach and influence among the research community to help us achieve our goals.

Our aim is to truly be within the research community, helping researchers to build important networks and make connections that will drive more and better research into brain tumours.

Goals for 2024/25

Hold two online training events for our Future Leaders with external speakers.

Agree a date in 2025/26 to hold our first-ever in-person Future Leaders event.

Increase awareness of The Charity among researchers by sponsoring, exhibiting and attending research conferences.

Send a quarterly e-newsletter for our research community and grow the size of our mailing list.

Hold four engagement events for the research community.

Outcomes

We held three online training events for our Future Leaders with external speakers.

Our in-person Future Leaders event took place on 12-13 June 2025.

We sponsored the International Symposium on Paediatric Neuro-Oncology (ISPNO), exhibited at the Society of Neuro-Oncology (SNO) Annual Meeting and the European Association of Neuro-Oncology (EANO) Annual Meeting, as well as attending the Cancer Research UK Brain Tumour Conference and the British Neuro-Oncology Society Annual Conference.

Sent a quarterly e-newsletter for our research community and grew the size of our mailing list by more than 7%.

We supported three lab tours.

HIGHLIGHTS OF 2024/25

Investing further in our Future Leaders

We've been delighted to watch our Future Leaders programme go from strength to strength. We now have ten Future Leaders across two cohorts, as well as our two Junior Fellows (the second stage of the programme).

The success of the programme shows that making this funding available for early-career researchers encourages them to establish themselves as leaders in the field. This is further evidenced by the fact that in 2024/25, two of our researchers – Dr Tyler Miller and Dr Ángel Álvarez-Prado – have been able to set up their own labs and are now leading teams of their own. You can find out more on page 11.

It's been incredible to bring the brightest early-career researchers together and see them support each other with their research. The mentorship that's provided as part of this programme is also proving invaluable to our Future Leaders.

Connecting researchers with the community

Whether it's at lab tours, fundraising events or special occasions like our Quality of Life sandpit, we're committed to keeping our researchers connected to the brain tumour community.

We do this because it makes sure the lived experiences of people affected by a brain tumour are central to the research we fund.

SUPPORT WORKFORCE INFRASTRUCTURE

Research into brain tumours is chronically underfunded. Together, we've been working hard to change this, but this historic lack of investment has meant fewer opportunities for researchers in the field – which has affected the number of researchers working towards finding cures for brain tumours.

We want to change this by supporting early-career researchers and making sure the most talented researchers are attracted to the field of neuro-oncology – as well as retaining that talent. We're also dedicated to improving research infrastructure so that more clinical trials can happen.

“Working at The Brain Tumour Charity taught me the importance of funding in advancing research and gave me first-hand insight into how science and compassion come together to fuel progress.”

Raz Methuen, Former Research Intern

Goals for 2024/25

Identify the biggest gaps in the research workforce.



Outcomes

We're in the process of reviewing the current challenges facing the research workforce and the initiatives already in place to support this – helping us better understand how we can have the biggest impact.

HIGHLIGHTS OF 2024/25

Two of our Future Leaders set up their own labs

We were delighted to see two members of our Future Leaders programme establish their own labs in 2024/25.

In June 2024, it was announced that Dr Tyler Miller was setting up his own research lab at Case Western Reserve University School of Medicine in the US. Dr Miller is one of our Junior Fellows, which is the second stage of our Future Leaders programme.

The team at his new lab will be focused on developing immunotherapies to treat brain tumours.

In March 2025, we learned that Dr Ángel Álvarez-Prado – part of our 2022 cohort of Future Leaders – would be leading his own research group at the Luxembourg Institute of Health. His research group will be studying how changes in DNA affect the immune system's fight against cancer and how this impacts the success of treatments.

“The brightest people in the world have options and the choices they make depend upon the opportunities that are presented to them. The Brain Tumour Charity gives them the opportunity to lead the world in brain tumour research.”

Professor Richard Gilbertson, Li Ka Shing Chair of Oncology and Senior Group Leader at the Cancer Research UK Cambridge Institute.


RAISING OUR VOICES TO CAMPAIGN FOR CHANGE

To build powerful momentum and push policymakers to go further, faster in defeating brain tumours, we're committed to bringing more people together who share our goals and helping them become champions for the brain tumour community.

Together, we'll increase our impact as we raise awareness of brain tumours and strive to improve experiences for everybody affected by a brain tumour at every step of their pathway.



Dr Scott Arthur MP with one of
our Involvement Champions



DEVELOP AND IMPLEMENT A NATIONAL BRAIN TUMOUR STRATEGY

To make a bigger impact, we need to turn up the volume of our calls for change and we can only do this by increasing the number of people who get behind our campaigning activity. We know that we also need to engage the right stakeholders at the right time to make a difference on pertinent policy issues.

Improving awareness of brain tumour signs and symptoms is also a priority. Through campaigns and incentives like our Better Safe Than Tumour campaign, we aim to increase the number of people who can name at least two symptoms of a brain tumour.

Goals for 2024/25

40,000 people to sign open letter calling for a National Brain Tumour Strategy between the launch in March 2024 and closing it in April 2024.

300 people to take 'Write to MP' action, asking them to support a National Brain Tumour Strategy.

Hold parliamentary engagement events in all four devolved nations.

10 Parliamentary Questions related to the awareness and treatments of brain tumours.

Outcomes

52,000 people signed our open letter between the launch in March 2024 and closing it in April 2024.

3,400 people took our 'Write to MP' action.

We held parliamentary engagement events in three nations and attended events in all four nations across the UK.

43 government responses to our Parliamentary Questions across all four nations.

HIGHLIGHTS OF 2024/25

We continue to push for progress through a National Brain Tumour Strategy

In April, we handed in our open letter at each of the parliaments across the UK that called on the government to implement a dedicated National Brain Tumour Strategy. This was supported by four groups of cross-party politicians who wrote to each of their respective devolved nations' Health Ministers to echo our calls for a National Brain Tumour Strategy.

But we haven't stopped there. In October, we launched a campaign encouraging people to write to their MP and invite them to discuss a National Brain Tumour Strategy with us. In total, more than 3,400 took part, resulting in us reaching MPs in over 94% of constituencies and has led to direct contact with more than 120 MPs.

Strengthening partnerships and platforms

Throughout 2024/25, we've continued to strengthen our partnerships with coalitions including One Cancer Voice, Cancer52 and the Less Survivable Cancers Taskforce. Working together, we've advocated for more joined-up action on rare and less common cancers, as well as pushing for equitable access to diagnosis and treatment.

We've extended our reach across the devolved nations, too. Throughout the year, we held multiple events to engage a wide variety of stakeholders – from parliamentarians and GPs to NHS clinical leads and innovation partners – in England, Scotland and Wales. We also attended events in Northern Ireland.

Supporting The Rare Cancers Bill

We're incredibly proud to have supported Dr Scott Arthur MP in his fight to get the Rare Cancers Private Members Bill through the House of Commons and to have helped shape the Bill. After his father-in-law died just six months after being diagnosed with a glioblastoma, Scott experienced the all too familiar story of loss and confusion around why there were so few treatment options and so little progress to improve cure rates in this devastating disease.

The aim of the Rare Cancers Bill is to incentivise research and investment into the treatment of rare cancers, like glioblastoma

and many other types of brain tumours. The Bill passed its second reading after an emotional debate in which MPs shared personal stories and made it clear that we can – and must – do better for people affected by rare cancers.

There's still lots of work to be done before The Rare Cancers Bill becomes an Act of Parliament and we'll continue to be one of the driving forces behind the change that's so urgently needed.



Foyso! Choudhury,
Scottish Labour MSP
with our supporters

DEVELOP EVIDENCE LED POLICY AND INFLUENCE POLICY DEVELOPMENT

We're committed to developing robust policy positions that cover research, diagnosis, care and treatment that are grounded in trustworthy data and the lived experience of people affected by brain tumours.

As well as gaining the support of the community, these need to have a real-world impact in convincing policymakers to act on our behalf.

Goals for 2024/25

Publish two 'bitesize' pieces of the National Brain Tumour Strategy that focus on research participation and faster diagnosis.



Outcomes

We completed research to help us better understand the detailed issues surrounding GP direct access to imaging and patient participation in research. We published these findings in Summer 2025.

HIGHLIGHTS OF 2024/25

The 10-Year Health Plan: making sure the brain tumour community is recognised in national healthcare policy

In December 2024, we worked with the community to respond to the Government's call for evidence for the 10-Year Health Plan.

The plan aims to modernise the NHS through three "big shifts": moving care into communities, improving health technology, and detecting illnesses earlier. While improvements in these areas offer promise in the way that brain tumour care is delivered, we still need a National Brain Tumour Strategy to comprehensively address the unmet need in diagnosis, care, treatment and research.

We focused on these key areas in our response to ensure the needs of those facing this devastating disease are listened to. New incentives developed must consider the unique nature of brain tumours to ensure the community's care does not continue to fall further behind.

Turning insight into influence

To help strengthen our campaign for a National Brain Tumour Strategy, we developed two bitesize pieces that add to the evidence of unmet need in key areas - including faster, better diagnosis, and access to new, better treatments to improve outcomes for brain tumour patients.

Our Exploring GP Access to Imaging reports shed light on the barriers GPs in England and Scotland face in accessing MRI brain scans. Based on evidence from patients, GPs and clinical experts, the report found that clinicians are committed but constrained, with urgent reform needed if we are to reduce diagnostic delays.

Research access remains a core priority, too. Our Barriers to Participation in Research report reveals the challenges that still prevent many people affected by brain tumours from taking part in trials or donating tissue. Developed in collaboration with patients, carers, clinicians and researchers, this report reveals the systemic, cultural and geographic obstacles that prevent too many people from participating in research.

Conducting research at this level, where the insights are expected to have far-reaching impact, takes time. We're looking forward to working with NHS leaders and policy makers to develop practical recommendations that help to combat these challenges.



IMPROVING QUALITY OF LIFE AND PROVIDING SUPPORT AND BEST CARE

We're committed to making sure that everybody in the brain tumour community - no matter who they are or where they're being treated - has access to the care and support they need.

This goes beyond what's delivered in the hospital or the community and needs to be tailored to the individual needs and choices of people affected by brain tumours.

Ultimately, our goal is for everybody affected by a brain tumour to be able to live better and cope with the impact of a diagnosis while having access to the best wraparound care from all UK treatment centres.



Involvement Champions
23-25 cohort

INDIVIDUAL FRONTLINE SUPPORT

From the moment people are diagnosed with a brain tumour, we want to make sure they have access to the information and support they need.

Across our wide range of Support and Information services, we want to have a notable impact at the right moment for anybody who contacts us. To make sure we're meeting the needs of the brain tumour community, we strive to work with people who use our service to better understand our impact.

Goals for 2024/25

Outcomes

Improve access to our Support and Information services across all channels



- 95% of calls to our Support and Information line answered first time.
- 46% visibility in online search results for Support and Information website pages.
- Counselling waiting list no longer than four weeks.
- Two-day response time for emails.
- Two-day response time on requests to join Online Brain Tumour Support Groups.

- 75% of calls answered first time.
- 57% visibility in online search results for Support and Information website pages.
- Counselling waiting list was two weeks or less.
- Two-day or less response time for emails.
- Two-day or less response time on requests to join Online Brain Tumour Support Groups.

Increase the positive impact of our Support and Information services



- Score higher than 85% on all reported outcomes.

Out of 387 people who responded to surveys on the impact of our Support and Information services:

- 88% of people who contacted our Support and Information Line said it helped.
- 79% of people who used our free counselling service said it made a difference to their emotional well-being.
- 100% of children who attended a Family Day felt more confident and 100% of adults who attended felt better connected.

Grow our capacity across our Support and Information services



- Maintain current capacity for all other Support and Information services.

- The number of people we helped through individual support grew 6% to 12,958 people.
- The number of times we helped somebody through individual support grew 19% to helping people 18,109 times.

Grow our free counselling service to 800+ users per year.



Our free counselling service grew 74% year-on-year with 739 users.

HIGHLIGHTS OF 2024/25

Providing high quality services and meeting the needs of the community

2024/25 was a year in which we aimed to continue to meet the increased post-pandemic demand for our Support and Information services. A key goal for the year was maintaining the high quality we strive for and continuing to have a meaningful impact on the community.

Individual support continues to grow year-on-year, with the team helping 12,958 people (an increase of 6% year-on-year) on 18,109 occasions (an increase of 19% year-on-year).

One area that we did actively work to grow was our free counselling service. In 2023/24, we had 425 people enter the service and wanted to increase this to more than 800 people.

We knew that aiming to almost double the number of people entering this service in a single year was a very ambitious target. While we didn't quite achieve this goal, we were still able to grow the service by 74% and provide free counselling for 739 people.


Launching our new Benefits Checker tool

The financial impact of a brain tumour diagnosis can't be overstated. In 2016, we launched our Benefits and Money Clinic in partnership with Citizens Advice Rushmoor to help people affected by a brain tumour navigate the benefits system.

While our Benefits and Money Clinic remains one of our most popular services, we know that some people would prefer to use a digital tool to check what benefits they may be eligible for.

That's why we made the decision to launch our new Benefits Checker tool on the website. This enables people to answer a few questions and then receive information about the financial support they may be entitled to.

Since launching this in September 2024, it's been used by 331 people.



“ Without The Charity's support, I think I would have given up. It can often feel like you're fighting a constant battle with the benefits system - as well as coping with the impact of your diagnosis - so it's brilliant to have someone on your side. **”**

Micheal, who got in touch with the Benefits and Money Clinic



12,958

people helped through
individual support
(+6% YoY)



18,109

interactions between
our Support and
Information team and
individuals seeking
support (+19% YoY)



4,250

cases opened through
our Support and
Information line
(+4% YoY)



513

people supported
through our Benefits
and Money Clinic
(-7% YoY)



More than

£1m

claimed in new benefits
through our Benefits
and Money Clinic
(-6% YoY)



739

people entered our free
counselling service
(+74% YoY)



165

Brainy Bags sent out to
children affected by a
brain tumour



709

Paediatric Brain Tumour
Information Packs
sent out to parents
and carers of a child
recently diagnosed with
a brain tumour



4,602

Information Packs sent
to people affected by a
brain tumour



36,396

total members of our
Online Brain Tumour
Support Groups
(+14% YoY)



255

people took part in our
Family Days



Over

1.1m

active users of online
support information
across our websites



HEALTHCARE PROFESSIONAL ENGAGEMENT AND COMMUNITY INVOLVEMENT

We're committed to working with healthcare professionals across the entire care spectrum to improve the experiences of people affected by a brain tumour – whether that's helping optical professionals spot symptoms or making sure neuro-oncology teams know we're here to support their patients.

Community first is one of our core values and we live this every day by championing the voice of the community and the power of lived experience in all areas of our work.

Goals for 2024/25

Appoint research team responsible for validating our Improving Brain Tumour Care surveys and have the project underway.



Outcomes

The project to validate our Improving Brain Tumour Care surveys is currently on hold until 2025/26.

We also:

- Involved members of our Involvement Network in 123 projects across The Charity.
- Trained almost 3,500 optical professionals to recognise the symptoms of a brain tumour.
- Presented to 922 healthcare professionals over 19 events thanks to our Healthcare Engagement team.

HIGHLIGHTS OF 2024/25

Championing community involvement across The Charity

2024/25 was another strong year for community involvement with our Involvement Network participating in 123 projects that spanned various teams across The Charity including marketing, policy, support, events, fundraising and research.

49% of the involvement projects were focused on research, showcasing our commitment for centring the voice of people affected by brain tumours in discussions about how to accelerate new cures for brain tumours.

Our commitment to listening to the lived experience of the brain tumour community and using their insights to shape critically important work, was never more evident than at our Quality of Life Sandpit event (read more on page 9).

49%



of the involvement projects were focused on research

SUPPORT BEST PRACTICE AND EQUITY OF ACCESS AND CARE FOR ALL

Overarching goals until 2030

We want to discover what best-practice looks like across the entire care pathway - from diagnosis and first-line treatment to rehabilitation and palliative care. Once we have an evidence-based view of this, we want other organisations to aspire to meet that standard and for it to become central to care improvement policy work and programmes across the sector.

Where we find gaps in the care that's available, we'll strive to fill them by collaborating across the UK with partners that can help us meet unmet needs.

Goals for 2024/25

Launch of our Faster, Better Diagnosis GP Programme pilot.



Outcomes

Our Faster, Better Diagnosis GP Programme pilot is currently still being developed and is due to launch in 2025.

HIGHLIGHTS OF 2024/25

Faster, Better Diagnosis GP Programme pilot

This year we managed to do the bulk of the work on a new project designed to help GPs recognise the common signs and symptoms of a brain tumour and feel more confident in referring suspected brain tumour cases to achieve a faster, better diagnosis.

Throughout 2024/25, we've worked with a steering group of GPs, radiologists, neurologists and other healthcare professionals to develop the new campaign and training resources. We're now hoping to test the campaign across a number of pilot sites in 2025/26.

Our Improving Brain Tumour Care surveys have repeatedly highlighted that people are regularly experiencing delays in getting a diagnosis through primary care settings, so we're excited to begin seeing the impact of this programme and to empower more GPs and primary care staff to recognise and refer suspected brain tumour cases faster.

Tessa Jowell Centres of Excellence for Children announced

As a member of The Tessa Jowell Brain Cancer Mission, we're delighted to see the first six Tessa Jowell Centres of Excellence for Children announced in April 2024.



Tessa Jowell
Centre of Excellence

These awards follow rigorous assessments by healthcare professionals and patient representatives, including information provided by our Paediatric Improving Brain Tumour Care surveys.

Six centres gained this accreditation and all 15 centres that applied will now be part of the Tessa Jowell Network. This is positive as it means they'll be working collaboratively to raise the bar for the treatment, care and research for children with brain tumours across the UK.

RAISING FUNDS TO GO FURTHER, FASTER

None of the vital work that we do is possible without the generosity of our supporters. We owe a huge thank you to each and every person who donated or raised funds for The Charity throughout 2024/25.

Our organisational strategy is extremely ambitious and to be successful we know that we need to develop a sustainable approach to increasing our income year-on-year through effective stewardship of existing supporters and a bold plan for acquiring new supporters.



HIGHLIGHTS OF 2024/25

A record-breaking year for fundraising

We're delighted that we've been able to increase our income to match our rapidly growing ambitions as an organisation.

In total, our amazing community helped us to raise a staggering £15.3m in 2024/25. That's an 8% increase on the previous year and meant we exceeded our income target by £300,000.

£15.3M

raised in 2024/25!

Wickes partnership raised £2m over two years

Since our partnership with Wickes began in 2023, colleagues across over 230 stores and in the Support and Distribution centres have rallied together to fundraise through events, personal challenges and customer 50p asks in their stores.

The partnership raised an incredible £2m to help power our work across research, support and campaigning. But it hasn't just raised vital funds, it's also spread awareness with an estimated three million people each month hearing our adverts in-store.



We are delighted to win the
**BEST SHORT-TERM
PARTNERSHIP AWARD**
in 2025 for our partnership
with Wickes.

Our fundraisers go further for a cure

2024/25 was a monumental year for our fundraisers, whether they were taking part in events organised by The Charity and our partners or organising their own fundraising activity.

Our flagship event – The Twilight Walk – returned once again during Brain Tumour Awareness Month and raised an incredible £524,000. 1,215 people joined us for The Twilight Walk London, with a further 1,300 people walking it their own way at The Twilight Walk Own Walks up and down the country.

Our TCS London Marathon team had a record-breaking year with 135 people pounding the pavement and collectively raising an astounding £820,000. High up in the Alps, our fearless fundraisers took on another gruelling Everest in the Alps challenge and raised nearly £450,000 to help fund our future research.

A huge thank you to everyone who took part in an event to help raise funds for The Brain Tumour Charity in 2024/25 – from runs, bike rides and hikes to bake sales, quizzes and skydives.

£820,000

raised by our TCS London
Marathon team

Generous gifts

We're incredibly grateful to everybody who donated to The Charity in 2024/25, including the philanthropists, trusts and family-led partners who supported us. We were humbled to also receive several unexpected large gifts from long-standing supporters throughout the year.

Spectacular Supporter Groups

Year-on-year, our Supporter Groups continue to make a huge impact by helping to spread awareness and raise funds across the country. We never take for granted that so many in the community have chosen to make The Charity part of their or their loved one's legacy.

We're delighted that six new Supporter Groups joined us this year and have already raised £70,000 - with lots of exciting fundraising plans for the near future.

We want to wish a warm welcome to The Bobby Spencer Fund, The Adam Stimpson Fund, The Angus James Gibson Fund, Maynards, Matt Bayfield Legacy Fund and Guernsey "Jim" James Robillard Fund.

Last year was also notable as we saw our first Supporter Group achieve the milestone of raising a total of £1m. The Silas Pullen Fund was helped to reach this achievement thanks to a donation from the family of Rory St John, who sadly passed away earlier in the year following a brain tumour diagnosis.

6 new Supporter Groups joined us this year.

Testing the water with new fundraising initiatives

To grow income sustainably and engage new supporters, we explored new ways of raising funds in 2024/25.

We piloted a door-to-door fundraising campaign that brought in almost 600 new donors, as well as raising awareness of brain tumours with a whole host of new potential supporters.

600 NEW DONORS
joined us through a door-to-door fundraising campaign.

We're stronger together with our corporate partners

Throughout 2024/25, our corporate partners have helped us raise funds and spread awareness of brain tumours.

We were thrilled to be named as one of three founding charity partners of the newly created Majestic Wine Charitable Foundation. The Foundation focuses on creating long-term impact through sustained charitable giving and has already activated customer-facing fundraising initiatives in over 200 Majestic Wine stores that have the power to benefit The Charity.

We partnered with the iconic cinema brand Pearl and Dean to raise awareness of the common brain tumour signs and symptoms on the silver screen. Our Better Safe Than Tumour advert was screened to an estimated 1.6m cinemagoers.

1.6M

cinemagoers estimated to have seen our Better Safe Than Tumour advert.

Developing a dedicated fundraising strategy

Over the past year, we've been developing a new dedicated fundraising strategy to help us reach our ambitious aim of growing our annual income to £25m by 2030.

The comprehensive process has helped us better understand how to capitalise on new opportunities that we've identified and how to overcome some of the barriers that are currently holding us back.

We're ready to get started on some exciting programmes of work to set us up for short and long-term growth.

Wickes

THE
BRAIN
TUMOUR
CHARITY

CHARITY PARTNER FOR
2023 - 2025

TOGETHER AGAINST BRAIN TUMOURS



Brain tumours are the biggest cause of cancer in children and adults

EQUALITY, DIVERSITY AND INCLUSION

This year, The Charity has made meaningful progress in laying the foundations for a long-term, strategic approach to Equity, Diversity and Inclusion (EDI). We're proud of the steps we've taken to build a more inclusive organisation and to make sure EDI plans are underpinned within The Charity's strategy.

We've defined clear EDI goals aligned to our 2023-2030 strategic pillars - transform the research landscape, raise our voices to campaign for change and improve quality of life, provide support and make sure everyone has access to the best care. These goals focus on building robust baseline data, increasing access and inclusion across all areas of our work and ensuring strong governance and accountability.

However, we know there's always more we can do. Building a fully inclusive organisation requires sustained effort, transparency and partnership. We're committed to moving further, faster on that journey thanks to the continued support of the EDI Subcommittee of the board, EDI Champions, our fantastic charity team, volunteers and our community.

COLLECTING BASELINE DATA AND GATHERING INSIGHTS

We're collecting EDI data across our workforce and volunteers, as well as launching a brand development and audience insight project that has EDI as a central focus.

This will provide crucial information on how to reach and better support unmet needs.

BUILDING INCLUSIVE RESEARCH PRACTICES

Our Research team has progressed work to drive greater diversity in the research landscape, addressing barriers to diversity in grant applications and highlighting the importance of inclusive research design.

IMPROVING ACCESS TO SUPPORT AND SERVICES

We've advanced inclusive service delivery through pilot initiatives such as increasing meaningful community involvement and a renewed collaboration with Brainstrust to improve early access to support.

FUNDRAISING WITH INCLUSION AT ITS HEART

During the development of our new fundraising strategy, we made sure that EDI was a core element from the outset, focusing on inclusive team culture and growing supporter networks among currently underserved communities.

CREATING A CULTURE OF BELONGING AT WORK

We have a highly engaged team at The Charity. During 2024/25, we've introduced new policies including Disability Leave, a Menopause at Work policy and enhanced Sickness Pay.

Awareness-raising initiatives, inclusive recruitment and our vibrant EDI Champions Group are supporting us to create a strong sense of belonging across The Charity.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)

A social ethos is intrinsic in The Charity since its purpose of existence is to serve the brain tumour community and drive change, and our values reflect this. We have comprehensive policies on matters such as anti-modern slavery and, through our Governance and Ethics committee, keep under constant review our partnerships to ensure the highest ethical standards in all our relationships.

REDUCING ENVIRONMENTAL IMPACT

Every team in The Charity considers what changes, big or small, they can make to reduce the environmental impact of what we do. Our Sustainability Champions group also meets regularly to review the actions being taken, make suggestions for improvements and keep environmental considerations at the forefront of people's work and personal life. This year, we added to our Cycle to Work scheme by offering staff the option of leasing Electric Vehicles which several members of staff have taken advantage of, replacing their combustion engine vehicles. We also continue to implement sustainable practices and strive to protect the environment by, for example:

- not using balloons
- avoiding lamination, coating and binding, as these reduce recyclability
- making a conscious effort to use local suppliers, and printers who are ISO 14001 certified and who report on their environmental impacts

- encouraging Twilight Walk participants to reuse t-shirts from previous years
- recycling and refurbishing old fundraising stock
- discontinuing plastic bag use.

We are a member of ECO Hub, a 700-charity-strong social media forum dedicated to reducing the environmental impact of charities across the globe. We share ideas and information and engage in constructive discussion to find alternative solutions, to make a positive impact.



FINANCE REVIEW

Income grew 8% in the year to March 2025 to a record £15.3m for The Charity, exceeding our budgeted expectation of £15m. The income is vital to funding the essential work The Charity does improving the lives and outcomes of those affected by brain tumours.

Expenditure on charitable activities increased by 7% year-on-year, driven by expenditure on awards into world-class scientific research. In the year to March 2025, research related expenditure was £7.7m, representing 50% of income. Within this research expenditure, our direct research grants grew from £5.4m to £6.2m but didn't achieve our ambitious aim of £7.5m, with some unavoidable delays in making some awards.


INCOME

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments. In the year, income was up year-on-year and £0.3m ahead of our budget for the 2024/25 with no income streams substantively under-performing.

Our Corporate income was £1.7m, in line with our expectations, and was bolstered from the second year of our partnership with Wickes.

Events and celebrity foundations income was 14% up compared to 2023/24 and 15% up on our budgeted expectation. Our TCS London Marathon team of a record 135 runners and the fearless fundraisers who undertook the gruelling Everest in the Alps event added to the many other participants raising money in the year.

Our Community Fundraising and Supporter Groups, having grown in 2023/24, didn't achieve the ambitious 11% growth we had budgeted for 2024/25 but still achieved an impressive £3m of income in 2024/25 through the hard efforts and generosity of our many community supporters.



EXPENDITURE

Expenditure in the year increased by £0.7m to £15.3m which was below our budgeted expenditure of £17.1m.

One of The Charity's primary objectives is to fund quality research and we aim to spend half of our income in this area as it's vital to us achieving our ambitious objectives. Expenditure on research, which comprises of both the current year's instalments of grant awards to institutions performing the research and The Charity's costs of running and managing this process, increased by £0.7m year-on-year to £7.7m. Of this £7.7m, £6.2m was on research grants, up on the £5.4m spent in 2023/24 but did fall short of the ambitious £7.5m we were aiming to spend with only two of the planned four new translational awards being ready to award before the end of the financial year.

Expenditure on support for those affected by the disease increased by 6% over 2023/24, in line with plans. Campaigning and awareness expenditure decreased by 8% year-on-year following an above usual spend in 2023/24 and in line with budget. These areas form the other main strands of The Charity's primary objectives, to support those affected by brain tumours, to campaign for improved healthcare, research and treatments and to raise awareness of the disease.


In 2024/25, spending on The Charity's charitable objectives represented 80p of every pound we spent.

In 2022/23, The Charity formed trading subsidiaries to commercialise the intellectual property developed by The Charity in creating its BRIAN app and database, with the intention they become a source of income for The Charity in the future by donating any profits to The Charity.

In May 2024, as stated in the Annual Report 2023/24 Finance Review, it became apparent that this endeavour was taking longer than anticipated to grow to a point of reaching a positive contribution and the decision was taken to terminate the operational activities of this venture and cease any further expenditure, beyond the minimum to meet statutory requirements. The loans from The Charity to the subsidiaries have been fully provided for and the Trustees have made appropriate filings to the Charity Commission.

In August 2024, The Charity made the difficult decision to terminate its BRIAN application and database to focus resources on other activities. Despite a loyal following for the application and a great deal of effort over many years to build a database that could make a real difference, it was decided that resources could be better utilised in other areas.

The Charity also has a trading subsidiary, TBTC Trading Limited. This subsidiary, which is wholly owned by The Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a trading profit of £9,000 which will be donated to The Charity.



INVESTMENTS AND CASH

World stock markets were highly volatile over the financial year, driven in large part by announcements by the US Government. At the end of the financial year, The Charity's investments were valued at £12.9m, down from March 2024 after £2m was converted from investments into cash in December 2024 to fund The Charity's work and maintain working capital. Realised and unrealised gains on investments in the year were £0.3m. All investments are held in highly liquid assets and the high level of cash held by The Charity facilitate being selective on when investments are liquidated to avoid losses due to short-term volatility. Current forecasts don't expect the investments to need to be liquidated in the next 12 months. Cash held as at 31 March 2025 was £5.2m.

RESERVES POLICY

The Charity's Reserves Policy is intended to ensure the long-term sustainability of The Charity, its ability to fund committed research expenditure and maintain its core services and Charitable Objectives by ensuring an adequate level of reserves are maintained to manage through a crisis.

Each year the Trustees review forecasts of income, expenditure, cash flows and reserves, to ensure The Charity maintains the level of reserves sufficient to manage a reduction of income that cannot be offset by a reduction in expenditure. In deciding on the level of reserves, the Trustees consider the risk and impact of potential unforeseen events and the ability of The Charity to react to such events.

In addition to considering income and expenditure, the Trustees ensure The Charity maintains a high level of liquid assets to meet foreseen and unforeseen circumstances and to meet our research commitments.

At 31 March 2025, the target level of unrestricted general reserves was £1m. This has been calculated as being the higher of:

- £1m or,
- the sum of 25% loss of income from forecast for 2025/26 levels equating to £3.9m, being offset by 25% savings of non-committed operating expenditure calculated as £2.0m and delaying budgeted new research awards of £1.6m, giving a value of £0.3m. This calculation quantifies the potential loss of income and ability to react.

The £1m minimum unrestricted reserve target is on the basis that the Trustees consider it appropriate to always maintain a minimal reserve to fund closure of The Charity in an extreme event.

The level of total Funds at 31 March 2025 was £8.8m, consisting of unrestricted General reserves of £1.9m, unrestricted Designated of £5.6m and Restricted of £1.3m. Free reserves, defined as general reserves of £1.9m less functional fixed assets of £0.2m, were £1.7m. Total unrestricted reserves are £7.5m, the unrestricted general reserves were £1.9m, £0.9m above the target level of £1m.

Designated funds are set aside by Trustees for specific purposes. Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group, amounting to £0.6m. The Trustees have also designated £5m, to be used to fund future programmes that are planned, including £3m on research, £1m on support services and £1m on fundraising to support the strategic and sustainable growth of The Charity. Designated reserves are expected to be spent in the next two years.

At 31 March 2025, we had unaccrued but committed research expenditure totalling £13m which was subject to satisfying our ongoing monitoring requirements. The investments and cash at 31 March 2025 (which are all liquid) were £18.1m.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's Investment Policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

INVESTMENT POLICY

The investment of funds is controlled by the Trustees who have appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Two investment managers, Albert E Sharp and Evelyn, have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £12.9m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash. The portfolio generated income of £581,000 and a valuation gain of £261,000.

In addition to managed investment funds, in 2022/23 The Charity formed subsidiaries to commercialise the intellectual property and technology it had developed in creating BRIAN, The Charity's database tool. As stated in the Expenditure section above, these activities ceased in May 2024 with provisions made in prior years for loans made to subsidiaries that may not be repaid.

EMPLOYEES

The Charity operates an equal opportunities recruitment policy and also champions equality, diversification and inclusion. The Remuneration Committee is responsible for overseeing The Charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.


The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

The work we do wouldn't be possible without the incredible contribution we receive from our volunteers. We currently have active volunteers across the UK who support in different roles within the organisation. Voluntary activities include: supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting a variety of projects.

RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership's regular management focus. The Governance and Ethics Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how we endeavour to mitigate these, are:

- **That we fail to secure adequate income.** We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain adequate reserves. We have no overreliance on any one income. The investment in CRM systems helps optimise stewardship plans.
- **That we are the victim of cyber-crime or that our IT infrastructure is not adequate to support our activities.** We have invested in growing our in-house IT capacity and capability, growing the size and skills of our team. We have reviewed and updated our systems and policies, investing in reputable and leading software solutions as well as utilising outsourced capability where necessary. We ensure that we have leading-edge malware protection and cyber security.
- We utilise multi-factor authentication and encryption and conduct appropriate staff training on cyber security. Online banking arrangements include double authorisation of all transactions and security devices. All websites use SSL technology. In addition, we have a cyber insurance policy.
- **That we become affected by damage to our reputation, or by negative sentiment in the charity sector.** We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups. We undertake careful recruitment of staff and volunteers and associated training, having strong policies and process to adhere to laws and regulations. We're cautious with who we work with and partnerships we engage in and conduct due diligence checks on significant partners. We have strong safeguarding procedures with an experienced safeguarding team.
- **That we aren't able to commission enough high-quality research projects.** We're developing our engagement with the research community into brain tumours and working to build capacity in the sector. We've developed our Future Leader programme to encourage and support world-class talent to enter and stay within the brain tumour research field. We fund globally and put significant emphasis on building relationships with key researchers.



OBJECTIVES FOR 2025-26

The Charity's objectives remain aligned to its core values and our priority objectives for the year are:

- Transforming the research landscape.
- Raising voices to campaign for change.
- Improving quality of life and providing support and the best care for everyone.

In addition to achieving The Charity's core objectives, The Charity will undertake numerous projects to:

- Accelerate income growth.
- Strengthen the organisation including investing in the right systems to protect The Charity and everyone we interact with and maintaining our culture.

PLANS FOR THE FUTURE

Our vision remains unchanged: for everyone diagnosed with a brain tumour to live longer, better lives.

We're investing time and effort on expanding our fundraising to grow and provide income for years to come, money

that will be used to fund our ambitious year-on-year investment in the best global research.

Our current strategy will guide us to 2030 and will set our direction and the shape we need to become in future years.



THANKS

Last year, The Charity continued to fund our existing commitments to the highest quality research as well as raising awareness and supporting thousands of people affected by a brain tumour.

The work is only possible due to the unprecedented support from the community and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us.

To everyone involved, we can't thank you enough for continuing to help us to strive to defeat brain tumours.

In addition to the donors named below, we'd like to thank all of our anonymous donors.

TRUSTS AND FOUNDATIONS

The AOK Trust
Maurice Hatter Foundation
The Netherdale Trust
The Colin Oliphant Charitable Trust
The Reed Foundation
The Syncona Foundation
The James Tudor Foundation
Garfield Weston Foundation

FAMILY-LED CHARITY PARTNERS

Angel Child
Iggy's Fund
James Clifford Campling Trust
Joss Searchlight
Shay's Smiles
Team Syren
The Albie Sugden Foundation
The Emily Morris Fund
The Jake McCarthy Foundation
The Oli Hilsdon Foundation
The William Low Trust

CORPORATE PARTNERS

Allports Group
Bank of England
BPL Global
British Council for Offices
British Horseracing Authority
Citi Belfast
CMS
DLA Piper
Ekco (formerly Bluecube Technology Solutions)
Gallagher
Gowlings Solicitors
Hollis
Knight Protection
Liberty Specialty Markets
The Majestic Charitable Foundation
The Puppet Company
Wickes Group PLC
Winckworth Sherwood

CO-FUNDING PARTNERS

Brain Tumour Research
Cancer Research Horizons
Cancer Research UK
Worldwide Cancer Research

HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

Nicki Chapman
Hal Cruttenden
Tom Daley
Dawn French
Sherrie Hewson
Miles Jupp
Sophie Kinsella
Dominic Matteo
Holly Matthews
John Maynard
Vicki Michelle
Lewis Moody
Amy Nuttall
Sian Reese-Williams
Marc Silk
Lord Spencer
Phil Spencer
The Wanted

SCIENTIFIC ADVISORY BOARD (SAB)

Chair

Prof. Steve Clifford

Vice Chair

Dr Susan Chang

SAB members

Dr Omer Bayraktar
Dr Adrienne Boire
Prof. Benjamin Deneen
Dr Phedias Diamandis
Dr Mariella Filbin
Dr Catherine Flores
Dr Mark Gilbert
Prof. Cynthia Hawkins
Prof. Marcel Kool
Dr Stephen Mack
Dr Tyler Miller
Prof. Simona Parrinello
Dr Lucy Stead
Dr Gerry Thompson
Dr Spencer Watson
Prof. Colin Watts

TRANSLATIONAL ADVISORY BOARD (TAB)

Chair

Prof. Petra Hamerlik

Vice Chair

Prof. Neil Carragher

SAB members

Prof. John Greenman
Dr Chris Ireson
Prof. Ruman Rahman
Dr Jann Sarkaria
Dr Karin Straathof
Dr Martin Swarbrick
Dr Cathy Tralau-Stewart

LAY ADVISORY BOARD (LAB)

Helen Brain
Shona Brooks
Kate D'Aubney
Viv Davies
John Graham
Karen Hong
Donald Innes
Neil Munn
Dean Richardson
Rick Taylor

QUALITY-OF-LIFE REVIEW PANNEL

Director

Prof. Jon Emery

Facilitator

Tim Morley

Quality-of-Life review panel members

Prof. Anne-Sophie Darlington
Dr Cheney Drew
Dr Jurgen Lemiere
Dr Antony Michalski

TRUSTEES AND GOVERNANCE

TRUSTEES

Dr Elena Bechberger
Hayley Conroy
Neil Dickson OBE (resigned 30/09/2024)
Dr Rachel Edgar (resigned 13/06/2024
and reappointed 21/03/2025)
Dr Russell Hagan
Sean Hird (resigned 31/12/2024)
Anna Jarvis
Justine McIlroy (resigned 30/09/2024)
Jack Morris CBE
Dr Alan Palmer (resigned 30/09/2024)
Dr Kieran Palmer
Sukhdip Sandhu
Caroline Steel
Matimba Swana
Beth Worrall (resigned 13/06/2024)

The directors and trustees had liability insurance during the financial year.

GOVERNANCE

CHIEF EXECUTIVE OFFICER

Dr Michele Afif

COMPANY SECRETARY

Liam Heffernan

CHARITY REGISTRATION

CHARITY NUMBERS

England and Wales 1150054
Scotland SC045081

COMPANY NUMBER

08266522

PRINCIPAL AND REGISTERED OFFICE

Fleet 27, Rye Close, Fleet, Hampshire,
GU51 2UH

AUDITORS

Menzies LLP, Magna House, 18-32 London
Road, Staines-upon-Thames, TW18 4BP

BANKERS

Lloyds Bank Plc, 147 High Street, Guildford,
GU1 3AG

INVESTMENT MANAGERS

Albert E. Sharpe, 7 Elm Court Arden Street,
Stratford-upon-Avon

Evelyn Partners, 25 Moorgate, London

THE CHARITY'S OBJECTS

The objects of the Charity are for the
public benefit:

- 1) to relieve sickness and to promote and protect good health by supporting research into the nature, causes, diagnosis and treatment and social consequences of tumours of the brain and central nervous system and to publish the useful results of such research;
- 2) the relief of suffering of people with tumours of the brain and central nervous system and their families and carers, through the provision of information and support to them; and
- 3) to advance the education of the public in all areas relating to tumours of the brain and central nervous system.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed above.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 7 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from committees which have been established to advise on key areas of activity, which are:

- Finance
- Research
- Information and Support
- Governance and Ethics
- Equality, Diversity and Inclusion
- Remuneration

The Charity has formed Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. The Advisory Boards are supported by expert and lay advisors who kindly donate their time to support our work.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity's work and objectives, ensuring we represent and help the whole community we serve.

The EDI committee comprising of at least two members of the Executive team and two Trustees along with other members as required has the purpose of making The Charity more proactive in reducing disparities, enhancing consistency of effort, raising awareness as well as evidencing and reporting on progress. This is aided by a Champions Team made up from Charity staff who meet regularly to consider and drive forward on all areas of EDI within The Charity.



GRANT-MAKING POLICY

The Charity has established its Grant-making Policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our research strategy 'Accelerating a Cure' launched in 2021/2022. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and more than 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research team, supported by our Scientific Advisory Board. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all of our fundraising activity. We used the services of professional third-party fundraisers, Ethicall and Family First Professionals during the year, in a limited capacity to contact potential new donors and supporters. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity.

We received three complaints this year relating to fundraising.

There have been no breaches of the Code of Practice during the year.

WORKING WITH PARTNERS

We're committed to working with all partners including those in the pharmaceutical and biotech industry in order to meet our objectives. We remain vigilant that our independence is not compromised and we act in the best interests of our community at all times.

STATEMENT OF TRUSTEE'S RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.
- The Trustees are responsible for

keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They're also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we're aware:

- There're no relevant audit information of which the charitable company's auditor is unaware.
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 19 September 2025 and signed on their behalf by:



Jack Morris CBE

Chair of Trustees

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2025 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSION RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.
- the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
- We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.

- The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur. We considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:

- Posting of fraudulent journal entries
- Posting of fraudulent payments and receipts in the accounting software
- Authorisation, processing, and payment of fraudulent expenses
- Fictitious employees
- Timing of revenue recognition

Audit procedures performed by the engagement team included:


- Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
- Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
- Challenging assumptions and judgments made by management in its significant accounting estimates; and
- Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations
- Carrying out checks to establish the validity of employees, and
- Reviewing and verifying the basis on which income is recognised in the accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/ auditor's responsibilities](http://www.frc.org.uk/auditor's-responsibilities). This description forms part of our Auditors' report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



Janice Matthews
FCA (Senior statutory auditor)
for and on behalf of

Menzies LLP
Chartered Accountants
Statutory Auditor
Magna House,
18-32 London Road,
Staines-upon-Thames,
TW18 4BP

Date: 19 September 2025

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted Funds £'000	Restricted Funds £'000	Total 2025 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2024 £'000
<u>Income and expenditure</u>							
Income from:							
Donations and legacies	3	11,567	2,571	14,138	10,926	1,704	12,630
Other trading	3	510	101	611	925	77	1,002
Investments		581	-	581	563	-	563
Total income		12,658	2,672	15,330	12,414	1,781	14,195
Expenditure on:							
Raising funds		3,060	1	3,061	3,130	33	3,163
Charitable activities							
Research		5,390	2,330	7,720	4,766	2,241	7,007
Patient support		2,776	365	3,141	2,389	569	2,958
Campaigning & raising awareness		1,371	41	1,412	1,369	162	1,531
Total expenditure on charitable activities		9,537	2,736	12,273	8,524	2,972	11,496
Total expenditure	4	12,597	2,737	15,334	11,654	3,005	14,659
Net (expenditure)/income before gains and losses on investment assets		61	(65)	(4)	760	(1,224)	(464)
Realised and unrealised gains on investment assets		261	-	261	764	-	764
Net movement in funds for the year		322	(65)	257	1,524	(1,224)	300
Reconciliation of funds							
Balances at 1 April		7,202	1,329	8,531	5,678	2,553	8,231
Balances at 31 March		7,524	1,264	8,788	7,202	1,329	8,531


The Statement of Financial Activities includes all gains and losses recognised in the year. All incoming resources and resources expended derive from continuing activities. The notes on pages 47-61 form part of these financial statements

CONSOLIDATED BALANCE SHEET AS AT 31 MARCH 2025

Company number: 08266522

		Consolidated		Company	
	Notes	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Fixed assets					
Intangible assets	10	-	1	-	1
Tangible assets	11	200	221	200	221
Investment in subsidiaries	12	-	-	-	-
Investments	12	12,947	14,636	12,947	14,636
Current assets					
Stock		44	50	-	-
Debtors	13	1,044	1,478	1,148	1,498
Cash at bank		5,176	3,487	5,151	3,401
		6,264	5,015	6,299	4,899
Creditors					
Amounts falling due within one year	14	(10,523)	(11,242)	(10,562)	(11,222)
Net current (liabilities)		(4,259)	(6,227)	(4,263)	(6,323)
Provision for liabilities	15	(100)	(100)	(100)	(100)
Net assets		8,788	8,531	8,784	8,435
Funds					
General reserve		1,897	6,194	1,893	6,098
Designated funds		5,627	1,008	5,627	1,008
Unrestricted funds		7,524	7,202	7,520	7,106
Restricted funds		1,264	1,329	1,264	1,329
	19	8,788	8,531	8,784	8,435

The financial statements were approved by the trustees on 19 September 2025 and signed on their behalf by:



Jack Morris CBE
Chair of Trustees



Hayley Conroy
Chair of Finance Committee

The notes on pages 47-61 form part of these financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2025

	2025 £'000	2024 £'000
Net (expenditure) / income for the year (as per the statement of financial activities)		
Net income for the year	257	300
Adjustments for:		
Depreciation	22	29
(Losses) on investments	(261)	(764)
Income from investments	(581)	(563)
Decrease/(Increase) in stocks	5	(17)
Decrease in debtors	434	215
Decrease in creditors	(719)	(809)
Net cash (used in) provided by operating activities	(843)	(1,609)
Statement of cash flows		
Cash flows from operating activities		
Net cash (used in) provided by operating activities	(843)	(1,609)
Cash flows from investing activities:		
Dividends, interest and rents from investments	581	563
Purchase of computer software	-	-
Purchase of property plant & equipment	-	-
Sale/(purchase) of investments	1,951	(33)
Net cash provided by investing activities	2,532	530
Change in cash and cash equivalents in the year	1,689	(1,079)
Balances at 1 April	3,487	4,566
Balances at 31 March	5,176	3,487
Analysis of cash and cash equivalents		
Cash in hand	5,025	1,161
Notice deposits (less than 3 months)	151	2,326
Total cash and cash equivalents	5,176	3,487

Analysis of changes in net debt				
	At 1 April 2024	Cash from purchase of investments	Other Cash flows	At 31 March 2025
Cash	1,161	1,951	1,913	5,025
Cash equivalents	2,326	-	(2,175)	151
Net debt	3,487	1,951	(262)	5,176

NOTES TO THE FINANCIAL STATEMENTS

1. STATEMENT OF COMPLIANCE

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 36. The principal activity of the company and the nature of its operations are set out in the trustees' report starting on page 6.

2. ACCOUNTING POLICIES

(a) basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity ("The Charity") constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity's subsidiary undertakings, TBTC Trading Ltd, Acquist Data Holdings Ltd, Acquist Data Ltd, Medli Health Holding Ltd and Medli Health Ltd have been consolidated on a line by line basis. All Group companies prepare their accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £349,000 (2024: £346,000).

The financial statements have been prepared under the historical cost convention.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) Company status

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 36. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

(c) Income

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Legacy income is recognised when the charity has sufficient evidence that a gift has been left to it (through knowledge of the existence of a valid will and the death of the benefactor); receipt is probable (there has been grant of probate and conditions attached to the legacy are within the control of the charity), and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the charity, can be reliably measured.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when The Charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) Expenditure

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such as grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Employee Termination Benefits are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

(e) Stocks

Stock is measured at the lower of cost and net realisable value.

(f) Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Designated funds are unrestricted funds that are set aside by Trustees for specific purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) Fixed assets

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) Estimated useful lives

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) Investments

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) Donated assets and services

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at the estimated price we would pay in the open market.

(k) Operating lease

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) Pensions

The Charity operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independently of The Charity's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) Going concern

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. INCOME

a. Donations and Legacies

	Unrestricted £'000	Restricted £'000	Total 2025 £'000	Unrestricted £'000	Restricted £'000	Total 2024 £'000
Ordinary activities:						
Regular giving	439	74	513	381	75	456
Donations, appeals and fundraising	9,087	2,329	11,416	8,799	1,443	10,242
Gift aid	1,084	143	1,227	874	45	919
Legacies	957	25	982	789	141	930
Government grants	-	-	-	83	-	83
	11,567	2,571	14,138	10,926	1,704	12,630

Government grants consist of amounts received under the COVID Medical Research Charity Support Fund.

b. Other trading

Other trading income comprises income from fundraising events such as The Twilight Walk and community events £530,000 (2024: £900,000), product sales £78,000 (2024: £82,000) and services sales £3,000 (2024: £20,000).

4. ANALYSIS OF RESOURCES EXPENDED

	Direct Costs £'000	Grants £'000	Support Costs £'000	2025 Total £'000
Raising funds	2,773	-	288	3,061
Charitable activities:				
Research	1,426	6,206	88	7,720
Patient support	2,981	-	160	3,141
Campaigning and raising awareness	1,272	-	140	1,412
Total expenditure on charitable activities	5,679	6,206	388	12,273
Total expenditure	8,452	6,206	676	15,334

	Direct Costs £'000	Grants £'000	Support Costs £'000	2024 Total £'000
Raising funds	2,891	-	272	3,163
Charitable activities:				
Research	1,507	5,415	85	7,007
Patient support	2,806	-	152	2,958
Campaigning and raising awareness	1,399	-	132	1,531
Total expenditure on charitable activities	5,712	5,415	369	11,496
Total expenditure	8,603	5,415	641	14,659

5. RESEARCH GRANT COST ANALYSIS

	2025 £'000	2024 £'000
Research programmes	2,942	3,938
Research projects	2,311	758
Clinical trials	803	719
Fellowships	139	-
Conferences	11	-
	6,206	5,415

A breakdown of research costs by individual award is provided in note 21.

6. SUPPORT COSTS BY ACTIVITY

2025	Finance and human resources £'000	Central facilities & information technology £'000	Central management & governance £'000	Total £'000
Raising funds	52	167	69	288
Charitable activities:				
Research	16	51	21	88
Patient support	29	92	39	160
Campaigning and raising awareness	25	81	34	140
Total	122	391	163	676

2024	Finance and human resources £'000	Central facilities & information technology £'000	Central management & governance £'000	Total £'000
Raising funds	75	138	59	272
Charitable activities:				
Research	23	44	18	85
Patient support	42	77	33	152
Campaigning and raising awareness	36	67	29	132
Total	176	326	139	641

Governance costs of £97,000 (2024: £82,000) are included in central management & governance.

7. GOVERNANCE COSTS

	2025 £'000	2024 £'000
Auditor's remuneration	28	32
Trustee meetings	-	1
Legal and professional fees	19	1
Staff	50	48
	97	82

In addition to Auditor's remuneration for audit shown above, a further £3,840 was paid for accounting and tax advice (2024: £840). Trustees received no remuneration (2024: £nil). Trustees received no reimbursement for travel expenses in the year totalling £nil (2024: £127). The premium in respect of professional liability insurance covering trustee indemnity was £5,484 (2024: £5,179).

8. STAFF COSTS

	Consolidated		Company	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Wages and salaries	4,617	4,304	4,617	4,223
Social security costs	456	416	456	405
Payments to defined contribution pension plans	359	310	359	310
	5,432	5,030	5,432	4,938

During the year redundancy payments were made totalling £6,000 (2024: £nil).

The average number of employees during the year was 118 (2024: 116).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2025	2024
£60,001 - £70,000	6	2
£70,001 - £80,000	2	2
£80,001 - £90,000	2	3
£90,001 - £100,000	1	-
£100,001 - £110,000	-	-
£110,001 - £120,000	-	-
£120,001 - £130,000	1	-

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £776,000 (2024: £708,000).

9. TAXATION

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

10. INTANGIBLE FIXED ASSETS

Consolidated and Company	Computer Software £'000
Cost	
At 1 April 2024 and 31 March 2025	161
Depreciation	
At 1 April 2024	160
Charge for the year	1
At 31 March 2025	161
Net book value	
At 31 March 2025	-
At 31 March 2024	1

11. TANGIBLE FIXED ASSETS

Consolidated and Company	Leasehold Improvements £'000	Computers and Office Equipment £'000	Total £'000
Cost			
At 1 April 2024	292	174	466
Disposals	-	(128)	(128)
At 31 March 2025	292	46	338
Depreciation			
At 1 April 2024	72	173	245
Charge for the year	20	1	21
Disposals	-	(128)	(128)
At 31 March 2025	92	46	138
Net book value			
At 31 March 2025	200	-	200
At 31 March 2024	220	1	221

12. INVESTMENTS

(a) Subsidiary Investment

Equity investment in group undertakings

Cost	£
At 1 April 2024 and 31 March 2025	201

The Charity owns 100% of the £1 ordinary share capital of Medli Health Holding Limited, a company incorporated in England and Wales, company number 14368728. Medli Health Holding Limited owns 100% of Medli Health Limited, a company incorporated in England and Wales, company number 14371364.

The Charity owns 100% of the £1 ordinary share capital of Acquist Data Holdings Limited, a company incorporated in England and Wales, company number 13951266. Acquist Data Holdings Limited owns 100% of Acquist Data Limited, a company incorporated in England and Wales, company number 13951572.

The purpose of the above companies were to commercialise the intellectual property created in developing the BRIAN database, to generate income to be donated to The Charity.

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

	2025 £'000	2024 £'000
Turnover	77	74
Cost of sales	(53)	(45)
Gross profit	24	29
Other operating expenses	(15)	(7)
Profit before donation	9	22
Donation	(23)	(12)
Retained profit/ (loss)	(14)	10

At 31 March 2025 the aggregate assets of TBTC Trading Ltd were £51,000 (2024: £53,000), aggregate liabilities £42,000 (2024: £30,000) and shareholder's funds £9,000 (2024: £23,000).

The net trading loss of Medli Health Ltd consolidated is as set out below.

	2025 £'000	2024 £'000
Turnover	3	20
Expenditure	(81)	(402)
Retained (loss)	(78)	(382)

At 31 March 2025 the aggregate assets of Medli Health Ltd were £123,000 (2024: £142,000), aggregate liabilities £1,350,000 (2024: £1,291,000) and shareholder's deficit £1,227,000 (2024: £1,149,000).

Medli Health Holding Ltd, Acquist Data Holdings Ltd and Acquist Data Ltd did not trade during the year.

(b) General investments

Equity investment in group undertakings

	2025	2024
Consolidated and Company	£'000	£'000
At 1 April	14,636	13,838
Additions at cost	502	471
Disposals	(1,301)	(387)
Net unrealised profit/(loss) on revaluation	(890)	714
At 31 March	12,947	14,636
Historical cost	11,635	12,469

	2025	2024
	£'000	£'000
Investments at market value comprised:		
UK equities	2,859	3,191
Overseas equities	3,622	4,377
Property	297	239
Multi asset funds	782	887
Alternative investments	97	93
Fixed income securities	5,232	5,819
Cash held within the investment portfolios	58	29
Accrued income	-	1
At 31 March	12,947	14,636

Financial instruments

During the year income from listed investments was £492,000 (2024: £472,000) and interest on deposits £89,000 (2024: £91,000).

Financial assets measured at fair value through income and expenditure amounted to £12,947,000 (2024: £14,636,000) comprise fixed asset investments. The value of investments is calculated with reference to the market value of the shareholding.

13. DEBTORS

	Consolidated		Company	
	2025	2024	2025	2024
	£'000	£'000	£'000	£'000
Trade debtors	182	171	182	169
Accrued income and prepayments	805	1,161	805	1,161
Other debtors	57	146	3	40
Amounts owed by Group companies	-	-	158	128
	1,044	1,478	1,148	1,498

14. CREDITORS

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2025: £535,000 (2024: £357,000) of income was deferred and £357,000 (2024: £310,000), brought forward from previous periods, was released.

	Consolidated		Company	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Grants payable	9,464	10,424	9,464	10,424
Accruals and deferred income	624	459	618	446
Trade creditors	269	192	265	185
Other creditors	50	51	50	51
Social security and other taxes	116	116	165	116
	10,523	11,242	10,562	11,222

15. PROVISION FOR LIABILITIES

	Consolidated		Company	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
At 1 April and 31 March	100	100	100	100

The provision relates to the future cost of obligations under the terms of a property operating lease at Fleet 27.

16. RESEARCH COMMITMENTS

At 31 March 2025 The Charity had authorised commitments that were subject to outstanding conditions amounting to £12,969,000 (2024: £13,082,000), these are expected to fall due as follows:

	2025 £'000	2024 £'000
Within one year	5,276	5,237
Between one and two years	4,418	3,717
Between two and three years	2,149	2,858
Between three and four years	1,126	1,270
	12,969	13,082

The above commitments will be funded from reserves and future income.

17. OPERATING LEASE COMMITMENTS

The total of future minimum lease payments on operating leases are as follows:

	On Property		On Equipment	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Consolidated and Company				
Within one year	218	218	42	10
Between one and five years	195	467	69	28
	413	685	111	38
Operating lease charges in the year	218	216	27	10

18. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Consolidated			Company		
	Unrestricted Funds £'000	Restricted Funds £'000	Total 2025 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2025 £'000
2025						
Intangible fixed assets	-	-	-	-	-	-
Tangible fixed assets	200	-	200	200	-	200
Investments	12,947	-	12,947	12,947	-	12,947
Other current assets	3,062	3,202	6,264	3,097	3,202	6,299
Current liabilities	(8,685)	(1,938)	(10,623)	(8,724)	(1,938)	(10,662)
	7,524	1,264	8,788	7,520	1,264	8,784

	Consolidated			Company		
	Unrestricted Funds £'000	Restricted Funds £'000	Total 2024 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2024 £'000
2024						
Intangible fixed assets	1	-	1	1	-	1
Tangible fixed assets	221	-	221	221	-	221
Investments	14,636	-	14,636	14,636	-	14,636
Other current assets	1,540	3,475	5,015	1,424	3,475	4,899
Current liabilities	(9,196)	(2,146)	(11,342)	(9,176)	(2,146)	(11,322)
	7,202	1,329	8,531	7,106	1,329	8,435

19. FUNDS

Consolidated 2025	At 1 April 2024 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2025 £'000
Restricted funds:					-	
Research funds	999	2,205	(2,120)	-	-	1,084
Everest fund	-	3	(3)	-	-	-
Awareness funds	-	41	(41)	-	-	-
Support funds	330	423	(573)	-	-	180
	1,329	2,672	(2,737)	-	-	1,264
Unrestricted funds:						
General reserve	6,194	11,923	(11,481)	(5,000)	261	1,897
Designated funds	1,008	735	(1,116)	5,000	-	5,627
	7,202	12,658	(12,597)	-	261	7,524
	8,531	15,330	(15,334)	-	261	8,788

Company 2025	At 1 April 2024 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2025 £'000
Restricted funds:						
Research funds	999	2,205	(2,120)	-	-	1,084
Everest fund	-	3	(3)	-	-	-
Awareness funds	-	41	(41)	-	-	-
Support funds	330	423	(573)	-	-	180
	1,329	2,672	(2,737)	-	-	1,264
Unrestricted funds:						
General reserve	6,098	11,866	(11,332)	(5,000)	261	1,893
Designated funds	1,008	735	(1,116)	5,000	-	5,627
	7,106	12,601	(12,448)	-	261	7,520
	8,435	15,273	(15,185)	-	261	8,784

Consolidated 2024	At 1 April 2023 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2024 £'000
Restricted funds:						
Research funds	1,169	1,141	(1,311)	-	-	999
Everest fund	745	184	(929)	-	-	-
Awareness funds	159	4	(163)	-	-	-
Support funds	480	452	(602)	-	-	330
	2,553	1,781	(3,005)	-	-	1,329
Unrestricted funds:						
General reserve	3,985	11,395	(9,950)	-	764	6,194
Designated funds	1,693	1,019	(1,704)	-	-	1,008
	5,678	12,414	(11,654)	-	764	7,202
	8,231	14,195	(14,659)	-	764	8,531

Company 2024	At 1 April 2023 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2024 £'000
Restricted funds:						
Research funds	1,169	1,141	(1,311)	-	-	999
Everest fund	745	184	(929)	-	-	-
Awareness funds	159	4	(163)	-	-	-
Support funds	480	452	(602)	-	-	330
	2,553	1,781	(3,005)	-	-	1,329
Unrestricted funds:				-		
General reserve	3,843	11,313	(9,822)	-	764	6,098
Designated funds	1,693	1,019	(1,704)	-	-	1,008
	5,536	12,332	(11,526)	-	764	7,106
	8,089	14,113	(14,531)	-	764	8,435

PURPOSE OF RESTRICTED FUNDS

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 21.
Everest fund	The Everest Centre is a specified programme for Research into Paediatric Low Grade Brain Tumours.
Awareness funds	Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is Better Safe Than Tumour.
Support funds	Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated funds represent unrestricted funds set aside by Trustees for specific purposes. In addition to funds set aside by Trustees for research, fundraising and support services, they include accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. The Trustees have also, approved funding of a Chair position at a UK university and have designated other funds for Research and Support services.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or move to general reserves to designated funds.

20. RELATED PARTIES

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2025 The Charity was owed from TBTC Trading Ltd £36,726 (2024: £24,458).

The Charity owns 100 of the issued £1 ordinary shares of Acquist Data Holdings Limited, a company with the same registered address as The Charity. Acquist Data Holdings Limited wholly owns the share capital of Acquist Data Limited.

The Charity owns 1 of the issued £1 ordinary shares of Medli Health Holding Limited, a company with the same registered address as The Charity. Medli Health Holding Limited wholly owns the share capital of Medli Health Limited.

Acquist Data Limited and Medli Health Limited were formed to commercialise the intellectual property developed by The Charity in creating its BRIAN database and app.

At 31 March 2025 The Charity:

- Was owed £400,000 (2024: £400,000) from Acquist Data Ltd in the form of an intercompany loan.
- Was owed £31,702 (2024: £31,702) from Acquist Data Ltd on an intercompany balance.
- Was owed £860,000 (2024: £860,000) from Medli

Health Ltd in the form of intercompany loans.

- Was owed £89,185 (2024: £71,443) from Medli Health Ltd on an intercompany balance.
- The Charity has fully provided as a bad debt provision for the loans owed to it from Medli Health Ltd totalling £860,000 (2024: £860,000) and Acquist Data Ltd totalling £400,000 (2024: £400,000).
- Was owed £82 from Acquist Data Holdings Ltd (2024: £300).
- Was owed £158 from Medli Health Holding Ltd (2024: £199).

Acquist Data Ltd was owed £395,239 (2024: £345,958) from Medli Health Ltd and has provided £345,958 as a potential bad debt.

Trustees, their close family members and entities they control, made donations to The Charity totalling £319,610 (2024: £216,739) during the year. They also paid contributions totalling £nil (2024: £713) for purchases.

21. RESEARCH AWARDS

	2025 £'000	2024 £'000
Research and Innovation Centre for Paediatric Low Grade Brain Tumours (Everest) - Dr. David Jones	1,004	988
Quality of Life - Prof. Colin Kennedy	35	61
Quest for Cures - Dr. Paul Northcott	-	184
Quest for Cures - Dr. Todd Hankinson	-	20
Quest for Cures - Prof. Simona Parrinello	-	218
Quest for Cures - Prof. Richard Gilbertson	-	304
Quest for Cures - Prof. Neil Carragher	-	525
Quest for Cures - Prof. Louis Chesler	239	266
Quest for Cures - Dr. Rameen Beroukhim	282	315
Quest for Cures - Prof. Marcel Kool	317	259
Quest for Cures - Dr. Jun Ishihara	340	349
Quest for Cures - Prof. Juan Pedro Martinez-Barbera	332	273
CONNECT TarGeT - Prof. Darren Hargrave	-	176
Quest for Cures - Prof. Barry Pizer	288	-
Quest for Cures - Dr. Pau Creixell	105	-
Total Programmes	2,942	3,938

Clinical Biomarkers – Dr. Gelareh Zadeh	41	58
Future Leaders – Dr. Mara De Martino	75	-
Future Leaders – Dr. Jessica Taylor	71	-
Future Leaders – Dr. Christopher Mount	75	-
Future Leaders – Mr. Ola Rominiyi	75	-
Future Leaders – Dr. Ángel Álvarez-Prado	75	-
Future Leaders – Dr. Claire Vinel	75	-
Brain Tumour Data Accelerator – Dr. Matthew Williams	-	46
Future Leaders Junior Fellowship – Dr. Spencer Watson	150	150
Future Leaders Junior Fellowship – Dr. Tyler Miller	150	150
LMIC award – Prof. Alan Davidson	-	26
Expanding Theories – Prof. Michael Brown	-	59
Expanding Theories – Dr. Manish Aghi	-	69
ICR Centre of Excellence – Prof. Chris Jones	-	200
Expanding Theories – Dr. Lucy Stead	67	-
Expanding Theories – Prof. Khuloud Al-Jamal	56	-
Future Leaders – Dr. Bo Sun	62	-
Future Leaders – Dr. Antonio Carlos Fuentes Fayos	100	-
Future Leaders – Dr. Charlotte Eaton	75	-
Future Leaders – Dr. Mathew Clement	47	-
Future Leaders – Dr. Emily Bates	74	-
Expanding Theories – Dr. Elizabeth Cooper	72	-
Expanding Theories – Dr. Youri Hoogstrate	73	-
Cancer Tech Accelerator – Mr. Richard Mair	70	-
Centre for Genomic Regulation – Prof. Luciano Di Croce	28	-
Institute of Biomedical Research – Dr. Maria Alieva	24	-
The Translational Award – Prof. John Anderson	246	-
The Translational Award – Prof. Maya Thanou	275	-
Quality of Life – Dr. Faye Didymus	67	-
Quality of Life – Ms. Vicky King	43	-
Quality of Life – Dr. Sarita Depani	72	-
Quality of Life – Dr. Debbie Hicks	73	-
Total Projects	2,311	758
PNET5 – Prof. Pamela Kearns	-	22
High Risk Medulloblastoma – Prof. Simon Bailey	85	84
BRAIN MATRIX – Prof. Colin Watts	611	613
ARISTOCRAT – Prof. Susan Short	107	-
Total Clinical Trials	803	719
Chair of Translational Neuro-oncology – Prof. Petra Hamerlik	139	-
Conferences, workshops and other	11	-
Total Research Award Expenditure	6,206	5,415



thebraintumourcharity.org

Registered office: Fleet 27, Rye Close,
Fleet, Hampshire, GU51 2UH
© The Brain Tumour Charity 2025.
Registered Charity in England and
Wales (1150054) and Scotland (SC045081).

**THE
BRAIN
TUMOUR
CHARITY**